azacitidine has been researched along with Rectal Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doi, A; Fujii, T; Irie, S; Matsui, T; Ohno, N; Sahara, N; Sakamoto, N | 1 |
| Cornfield, DB | 1 |
| Fearon, ER; Hinoi, T; Loda, M | 1 |
3 other study(ies) available for azacitidine and Rectal Neoplasms
| Article | Year |
|---|---|
[Azacitidine for Therapy-Related Myelodysplastic Syndrome Following Oxaliplatin (L-OHP)Therapy for Metastatic Rectal Cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Fatal Outcome; Humans; Leucovorin; Male; Myelodysplastic Syndromes; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2018 |
Erythroblastic sarcoma, an extremely rare variant of myeloid sarcoma.
Topics: Abnormal Karyotype; Adenocarcinoma; Aged; Azacitidine; Biopsy, Large-Core Needle; Bone Marrow; Bone Marrow Neoplasms; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Erythroblasts; Erythropoietin; Fatal Outcome; Humans; Lymph Nodes; Male; Myelodysplastic Syndromes; Rare Diseases; Rectal Neoplasms; Sarcoma, Myeloid | 2012 |
Silencing of CDX2 expression in colon cancer via a dominant repression pathway.
Topics: Adenoma; Azacitidine; Blotting, Western; CDX2 Transcription Factor; Cell Division; Colonic Neoplasms; Cytoplasm; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Hydroxamic Acids; Immunohistochemistry; Methyltransferases; Mutation; Mutation, Missense; Phenotype; Phosphatidylinositol 3-Kinases; Rectal Neoplasms; Trans-Activators; Transcription, Genetic | 2003 |